News
Childhood cancer survivors over age 50 had a threefold higher mortality risk compared with the general population, primarily ...
BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ:BLRX) reported second quarter 2025 results, producing license revenues of $304,000. Following the transition of commercialization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback